Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

Aratana Therapeutics, Inc. (PETX)

(Delayed Data from NSDQ)

$4.75 USD

+0.11 (2.37%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.76 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[PETX]

Reports for Purchase

Showing records 1 - 17 ( 17 total )

Industry: Medical - Drugs

Record: 1

05/18/2019

Pages: 6

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

04/26/2019

Pages: 6

Elanco to Acquire Aratana for $245M in Stock; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

03/15/2019

Pages: 8

Continued Revenue Growth Expected in 2019; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

11/05/2018

Pages: 6

Strong Revenues Driven by Galliprant Sales; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

10/23/2018

Pages: 10

ValuEngine Detailed Valuation Report for PETX

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

08/06/2018

Pages: 6

Nocita Approved for Cats; Strong Revenue Growth in 2Q18; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

05/07/2018

Pages: 7

Nocita and Entyce Continue to Grow; Potential AT-003 Approval 2H18; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

03/19/2018

Pages: 7

Entyce Posts Strong Intial Sales; New Products in 2018; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

02/21/2018

Industry Report

Pages: 6

Three Notable Areas of Development in Companion Animal Health; Our Takeaways from VMX 2018

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

01/16/2018

Pages: 3

Galliprant Approved in EU; Additional Product Approvals Expected in 2018; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

12/21/2017

Pages: 3

AT-014 Conditional Approval: Further Attestation to Strategy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

11/17/2017

Pages: 19

A Commercial Stage Animal Health Biotech with a Proven Development Model; Initiate with Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

11/17/2017

Pages: 28

A New Wave of Biotechs Reshaping the Animal Health Market; Initiate Coverage on Aratana and Kindred Bio With Buy Ratings

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

09/01/2017

Industry Report

Pages: 8

A Wind of Change Is Blowing Through the Animal Health Market

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

03/23/2016

Industry Report

Pages: 5

Aratana reported on Monday that the Center for Veterinary Medicine

Provider: DAWSON JAMES SECURITIES, INC.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

03/23/2016

Pages: 5

A new era is underway in companion animal therapeutics and more specifically in the blending of companion animal, comparative biology/oncology and human health

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: GRISEWOOD S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

12/08/2015

Industry Report

Pages: 19

Comparative Oncology: A New Breed of Trial Set to Improve Clinical Success in Oncology

Provider: DAWSON JAMES SECURITIES, INC.

Price: 50.00

Research Provided by a Third Party